Bronchiolitis Obliterans Syndrome (BOS) is a well-recognized complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The management of bronchiolitis obliterans has been frustrating, with patients developing progressive Air Flow Obstruction (AFO). The purpose of this study was to evaluate the efficacy of human Bone Marrow Derived Mesenchymal Stem Cells (BMMSC) as the salvage therapy for BOS after HSCT. One patient with BOS received intravenous infusions of BMMSC at a dose of 1.5×10 6/kg per patients' weight, and rapid recovery from BOS without any side effects was observed. We concluded that BMMSC seems to be a promising therapeutic method in patients with BOS after HSCT.
- Bronchiolitis obliterans syndrome
- Hematopoietic stem cells transplantation
- Mesenchymal stem cells